{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "QURE",
  "name": "uniQure N.V.",
  "url": "https://orbyd.app/dossiers/QURE/",
  "json_url": "https://orbyd.app/dossiers/QURE.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA — the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on 7/02. Next leg needs a dated filing headline, not another upgrade.",
  "invalidation_trigger": "A weekly close below $34 (surrenders the rising 50-DMA and the pre-U-turn consolidation shelf); secondarily, the AMT-130 BLA slipping out of Q3 2026 or the confirmatory study reverting to a sham-surgery control.",
  "catalyst_date": "2026-08-04",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-08-06",
  "invalidation_fired": false,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Confirmatory-study design is the hidden swing factor: FDA is considering a concurrent standard-of-care control instead of the sham-surgery arm demanded on 2026-03-02. Reversion to sham reinstates the March problem and the multi-year burn attached to it.",
    "Insider distribution flag: CEO Matthew Kapusta exercised options at $19.39 and sold 21,082 shares at ~$44-46 on 2026-07-02 (10b5-1). Executives have been sellers, not buyers, since the June spike.",
    "Short interest 16.72% of shares outstanding — squeeze fuel on a filing headline, but equally a base of sellers that presses any timeline slippage.",
    "Solvency is not the risk: $586.6M cash/investments at 2026-03-31 plus the June raise, runway guided into H2 2029, current ratio 10.40. Burn is ~$172M/yr operating cash flow. Shares outstanding 68.75M, +20.23% YoY.",
    "Efficacy anchor: 75% slowing of progression on cUHDRS at 36 months, high dose, statistically significant vs propensity-matched external control (June 2025 readout). No approved disease-modifier exists in Huntington's.",
    "Watch CLPT (AMT-130 delivery device), RGNX (2026-06-22 Navsunli refile allowance) and CAPR (2026-06-26 adcomm scheduling) as regulatory-regime correlation reads.",
    "AMT-260 epilepsy cohort-1 data (2026-06-22) is 6 patients, uncontrolled, up to 6 months follow-up. Treat as option value, not a second pillar.",
    "The real binary is BLA acceptance / refuse-to-file ~60 days after submission, i.e. likely Q4 2026. Everything before it is positioning ahead of an unpriced gate."
  ],
  "body_markdown": "## Current Thesis\nThe regulatory story is repaired and the trade has already been paid out. On 2026-06-17 the FDA communicated, following a Type B meeting, that the three-year analysis from the AMT-130 Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval in Huntington's disease — a direct reversal of the 2026-03-02 position that external-control data could not support a marketing application. UniQure guided to a Q3 2026 BLA and a Q3 2026 UK MAA. The stock spiked, management immediately sold $225M of equity into it at $45.50 (2026-06-24), and price has since bled back to $40.25 (2026-07-17) — under the deal price, with the CEO selling on 2026-07-02. What is left is a funded, de-risked-on-paper filing story trading at $2.77B on $18.09M TTM revenue, waiting on a submission headline that has no date attached to it. The narrative leg an investor is buying now is not \"will the FDA allow a filing\" — that is answered and priced — but \"does the BLA land in Q3 with a standard-of-care confirmatory design intact.\" That is a thinner, later, and more binary bet than the one available five weeks ago.\n\n## Bull Case\n- **Dated agency reversal, not sentiment.** 2026-06-17: FDA accepts the three-year Phase I/II analysis as the primary basis for an accelerated-approval BLA; company guides submission to Q3 2026. The 2026-03-02 8-K had said the opposite.\n- **The confirmatory trial got materially cheaper.** FDA is considering a concurrent standard-of-care control rather than the sham-surgery design demanded in March. Sham neurosurgery control is the single hardest enrollment problem in this indication; removing it shortens the path and cuts the burn attached to it.\n- **Efficacy is not the question.** The June-2025 pivotal readout showed a statistically significant 75% slowing of disease progression on cUHDRS at 36 months at the high dose versus a propensity-matched external control. Huntington's has no approved disease-modifying therapy.\n- **Sell-side reset hard and has not walked it back.** 2026-06-18: Barclays Overweight PT $65, Leerink Outperform PT $70, RBC Outperform PT $65, Goldman PT $14 → $46. 2026-06-25: Mizuho Outperform PT $68. 2026-06-29: H.C. Wainwright PT $50 → $80. Cantor Fitzgerald and Wells Fargo both moved to Overweight. Consensus average PT sits near $65 across 13 analysts (higher, ~$71, across broader 22-analyst panels) against $40.25 spot.\n- **Funded through the event.** $586.6M cash and investments at 2026-03-31 plus ~$211.5M net from the June raise; runway guided into H2 2029; current ratio 10.40. No forced second raise before the filing decision.\n- **Second asset showing signal.** AMT-260 (refractory mesial temporal lobe epilepsy) first-cohort data, 2026-06-22: early seizure reductions, no treatment-related serious adverse events.\n- **Sector regime corroborates.** 2026-06-22: FDA reversed its rejection of REGENXBIO's Navsunli and permitted a refile — a second data point on an agency flexing toward rare-disease gene therapy.\n- **Structure is still constructive underneath.** Price holds above a rising 50-DMA at $34.03 and a 200-DMA at $29.45, golden cross intact, +179% over 52 weeks. Short interest at 16.72% of shares outstanding is real fuel if a filing headline lands.\n\n## Bear Case\n- **Price is under the deal.** The $225M offering priced at $45.50 on 2026-06-24 (4,945,055 shares) with the stock around $48.60. At $40.25 every buyer of that book is offside. That converts $45.50 from a support shelf into overhead supply — the first bid on any rally is the deal buyer getting out flat.\n- Management raised equity into the spike and personally distributed into it in the same fortnight.\n- **A filing path is not an approval.** The BLA must still be submitted, accepted, and reviewed, and FDA can re-attach conditions at any stage. The 15-week swing from the 2026-03-02 rejection of the external-control package to the 2026-06-17 acceptance shows the agency's stance on this file moves fast in both directions.\n- **The submission has no date.** \"Q3 2026\" spans July through September. A name whose next real move requires an undated press release is a poor risk-of-ruin profile against a 16.72% short base that will press any slippage.\n- **Valuation carries no cushion.** $2.77B market cap, $18.09M TTM revenue (-10.4%), -$208.87M net income, -$172.11M operating cash flow. Hemgenix contributes little. There is nothing to fall back on if the regulatory leg breaks.\n- **Dilution is structural, not one-off.** 68.75M shares outstanding, +20.23% year over year. Approval-stage build-out and a confirmatory trial argue for more of it.\n- **Epilepsy read is thin.** Six patients, up to six months follow-up, no control arm. It is a call option, not a second pillar.\n- **Adcomm risk is live in the sector.** Capricor's Deramiocel got a July advisory-committee meeting scheduled on 2026-06-26 and the stock fell. An adcomm attached to AMT-130 would add a binary that is not currently in the price.\n\n## Setup & Price Structure\nLast close $40.25 (2026-07-17, +2.26%), 52-week range $8.73–$71.50, +68.2% year to date from $23.93. The 50-DMA is $34.03 and the 200-DMA $29.45 — both rising, both well below spot, so the trend template is technically intact even after the fade.\n\nThe structure is a V, not a base. Price ran from the March low through the 6/17 spike into the high $40s, then gave back roughly 17% into mid-July on no negative news. There is almost no price memory between $30 and $50 — the tape moved through that band twice in four months without building a shelf, so pullbacks have nothing to lean on until the 50-DMA.\n\nThe battleground level is $45.50. A weekly close back above the offering price on expanding volume is the readable sign that the deal has been digested and the sellers are done; until that happens, rallies into the mid-$40s are meeting supply from a book that is underwater. On the downside, $34 is where the rising 50-DMA meets the pre-U-turn consolidation — losing that on a weekly basis says the regulatory re-rate is being unwound rather than consolidated.\n\nBeta of 0.90 is meaningless here. The realized distribution on this name is bimodal and headline-driven; the correct framing is a fully-funded filing story with a 16.72% short base and a wide, undated event window, which is why a starter-size approach and no adding into weakness are the only sane way to carry it.\n\n## Catalyst Calendar (next 30 days)\n\n- **Q3 2026, undated (any session from now)** — AMT-130 BLA submission to FDA. This is the actual catalyst and it can drop on any morning without pre-announcement.\n- **Rolling, no date** — confirmation (or contradiction) that the confirmatory study will run with a concurrent standard-of-care control rather than a sham-surgery arm. FDA wants alignment before the BLA goes in, so this headline should precede the filing.\n- **Q4 2026 (outside window, flagged)** — BLA acceptance / refuse-to-file decision, roughly 60 days after submission. That is the genuine binary; everything before it is positioning.\n\n## Elapsed catalysts\n\n- **~2026-07-31 to 2026-08-04 (est.)** — Q2 2026 financial results and pipeline update. Q1 was reported 2026-05-05; calendars split between 7/31 and 8/4, so treat the whole window as live. The value is not the P&L but the management commentary on BLA timing and confirmatory-study design. *(passed 5d ago)*\n- **Q3 2026, undated** — UK MAA submission to MHRA on the three-year data, following the 2026-04-30 pre-submission meeting. An independent, non-FDA route. *(passed 101d ago)*\n\n## What Would Change Our Mind\n- **Thesis-break condition:** a weekly close below $34 — that surrenders the rising 50-DMA and the pre-U-turn consolidation, and would mark the June re-rate as being unwound rather than digested.\n- **Bullish confirmation instead:** a weekly close above $45.50 on expanding volume, clearing the offering price and turning deal supply into support. That is the level at which the story re-earns size.\n- **BLA slipping out of Q3 2026** into Q4 or later, or Q2 commentary that hedges on submission timing.\n- **Any reversion of the confirmatory design to a sham-surgery control**, which reinstates the March 2026 problem and the multi-year, high-burn path attached to it.\n- **A refuse-to-file, or an advisory committee being scheduled for AMT-130** — the latter reads as agency hesitation and adds an unpriced binary.\n- **Continued insider distribution** on top of the 2026-07-02 CEO sale, particularly non-10b5-1 sales.\n- **Competitive Huntington's data** from PTC Therapeutics or Wave Life Sciences that compresses the first-mover premium the $65-ish consensus target is built on.\n\n## Correlation Notes\n- **RGNX (REGENXBIO)** — the 2026-06-22 Navsunli refile allowance is the purest read on whether the FDA's gene-therapy flexibility is durable or a one-file exception.\n- **CLPT (ClearPoint Neuro)** — supplies the neurosurgical delivery platform used for AMT-130; trades as a levered derivative of the AMT-130 commercial timeline. Divergence between the two is an early warning on filing conviction.\n- **CAPR (Capricor)** — the 2026-06-26 adcomm scheduling and subsequent selloff is the template for how this tape prices an unexpected advisory committee.\n- **SRPT, RCKT, TSHA, SLDB** — the AAV gene-therapy complex. A safety event anywhere in it (AAV liver toxicity, a clinical hold) hits the whole group regardless of program specifics.\n- **PTCT, WVE** — Huntington's competitors; positive competitor data is a direct negative here.\n- **XBI** — small-cap biotech beta. This name's regulatory-thaw premium survives a soft XBI tape but not a rate-driven one; it went to $8.73 in the last risk-off leg.\n- **Theme status: MATURING.** Rare-disease gene-therapy regulatory thaw was accelerating from mid-June to end-June; the upgrades have landed, the equity has been raised, and price is now below where the deal cleared. That is the signature of a theme in its digestion phase, not its discovery phase.",
  "first_seen": "2026-05-27",
  "last_analyzed": "2026-07-20T07:28:59+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "theme_discovery",
  "license": "Content © orbyd. Cite the canonical URL."
}